Compare Organon & Co. Common Stock (OGN) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs VanEck Rare Earth/Strategic Metals — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while VanEck Rare Earth/Strategic Metals trades at $54.5 (market cap $1.64B). The key difference: Organon & Co. Common Stock is far larger — about 2.2× VanEck Rare Earth/Strategic Metals's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and VanEck Rare Earth/Strategic Metals for 52 Days on average.
| OGN | REMX | |
|---|---|---|
Market Cap | $3.62B | $1.64B |
Volume | 2,892,999 | 710,568 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $109.53 |
52-Week Low | $5.70 | $55.78 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $57.45, down 1.25% amid bearish technical signals with moving averages indicating strong selling pressure. The ETF provides exposure to 38 global rare earth companies but faces high volatility and China concentration risks. Recent institutional activity includes Bank of America increasing its position by 72.1% in Q2 2026, while geopolitical developments around critical minerals supply chains continue to influence sentiment.
The outlook remains challenged by technical weakness and sector volatility, though oversold RSI readings suggest potential near-term bounce. Long-term prospects hinge on U.S. supply chain development and China export policies, but the ETF's 50% annualized volatility makes it unsuitable for conservative investors. Strategic importance of rare earths supports thematic interest despite execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
